Engage: A Telehealth-Delivered Psychosocial Intervention to Decrease Symptom Interference in Patients With Advanced Cancer

What this Trial Is About

Researchers are evaluating a new telehealth-delivered psychosocial intervention called ENGAGE for patients with Stage IV breast, prostate, lung, or colorectal cancer who experience moderate-to-severe symptom interference. This trial aims to test the effectiveness of ENGAGE in reducing symptoms like pain, fatigue, and distress that commonly affect quality of life in advanced cancer. The study compares ENGAGE to a Supportive Care intervention, focusing on patient-reported outcomes over time. Participants will be randomly assigned to receive either ENGAGE or Supportive Care. Both interventions involve four telehealth sessions lasting 45 to 60 minutes each, delivered by trained therapists. ENGAGE combines cognitive behavioral therapy and acceptance and commitment therapy techniques to teach behavioral symptom management skills and encourage engagement in meaningful activities. Supportive Care provides education, support, and resources addressing common cancer-related concerns such as symptoms, body image, and financial issues. During the study, participants will complete assessments at the start, 2 months, and 4 months to measure symptom interference and other outcomes using tools like the MD Anderson Symptom Inventory and PROMIS questionnaires. The research will track the impact on symptom severity, self-efficacy in managing symptoms, anxiety, depression, and quality of life. Data collection will also include feedback from patients, oncology providers, and clinic leaders to inform future implementation. The trial is expected to continue through November 2028.

Engage Psychosocial Intervention for Cancer Symptoms